Starting January 1, 2025, the Inflation Reduction Act's Part D redesign capped beneficiary out-of-pocket costs at $2,000 annually and eliminated the 5% catastrophic coinsurance that previously applied above the catastrophic threshold. Manufacturers now pay 20% of catastrophic-phase drug costs, up from zero under the prior design.
The financial impact is concentrated in high-cost specialty categories. CMS estimates the manufacturer catastrophic liability at $7-9 billion annually across all Part D drugs. The heaviest exposure falls on oncology, immunology, and rare disease products where per-patient annual costs regularly exceed $100,000.
For specific companies, the impact varies by Part D exposure. Johnson & Johnson estimated a $900 million annual hit from the Stelara and Imbruvica catastrophic share. Bristol Myers Squibb projected $500-700 million from Eliquis and Opdivo. Companies with concentrated Part D portfolios face the steepest margin compression.
The redesign also changes the calculus on launch pricing. Under the old structure, manufacturers bore no catastrophic cost. Now, every dollar of list price above the catastrophic threshold generates a 20% manufacturer liability. This creates a mathematical incentive to launch at lower price points, particularly for drugs with large Part D populations.
